Abstract
BACKGROUND: This study aimed to assess the significance of combined expression of interleukin-2 receptor (CD25) and the interleukin-3 receptor (CD123) in acute myeloid leukemia (AML) patients.
METHODS: The expression of CD25 and CD123 on blast cells in bone marrow samples were identified by flowcytometry in 94 patients (<= 60 years old) with de novo acute myeloid leukemia (AML) treated at the Mansoura University Oncology Center (MUOC).
RESULTS: Of the 94 samples at diagnosis there were 17 (18.1%) CD25(+)/CD123(+) (double positive) cases; 25 (26.6%) CD25(+)/CD123(-) (single positive); 32 (34.0%) CD25(-)/CD123(+) (single positive) cases; 20 (21.3%). CD25(-)/CD123(-) (double negative). Most of the AML patients have double CD25(+) /CD123(+) were significantly associated with poor and intermediate risk as compared to those associated with those in the good risk group (P = 0.005). The lowest induction of remission was recorded in AML patients have double CD25(+)/CD123(+) expression as compared to the remaining AML patient group. Study the effect of these biomarkers on the overall survival reveal that AML patients exhibited double CD25(+)/CD123(+) expression had significantly shorter overall survival as compared to negative ones.
CONCLUSION: Double CD25(+)/CD123(+) co-expression in AML patients is a dismal prognostic marker and could be used as novel biomarker for risk stratification for AML patients.